Received Aug 21, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
how to proceed with the dosing schedule; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 60-year-old female patient who received HBV (Engerix B) for prophylaxis. Previously administered products included Engerix B (received 1st dose on 10-MAR-2025 with batch number T5D73 and lot expiry 10-APR-2027). On an unknown date, the patient did not receive the 2nd dose of Engerix B. On an unknown date, the patient had incomplete course of vaccination (Verbatim: how to proceed with the dosing schedule). The outcome of the incomplete course of vaccination was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 19-AUG-2025 The pharmacist reported that the patient received the Engerix-B vaccine on 10-MAR-2025, that was her 1st an only dose, so the reporter to find out how to proceed with the dosing schedule. The vaccine administration facility was the same as primary reporter. Till the time of reporting, the patient did not receive 2nd dose of Engerix B vaccine, which led to incomplete course of vaccination.